Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V.

M. Nijhuis; A.M.J. Wensing; W.F.W Bierman; D. de Jong; R.M. Kagan; A. Fun; C.A.J.J. Jaspers; C.A.M. Schurink; M.A. Agtmael; C.A.B. Boucher

Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V.

Translated title of the contribution: Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V.

M. Nijhuis, A.M.J. Wensing, W.F.W Bierman, D. de Jong, R.M. Kagan, A. Fun, C.A.J.J. Jaspers, C.A.M. Schurink, M.A. Agtmael, C.A.B. Boucher

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V.
Original language	Undefined/Unknown
Pages (from-to)	698-709
Number of pages	11
Journal	Journal of Infectious Diseases
Volume	200
Issue number	5
Publication status	Published - 2009

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/19627247

Cite this

Nijhuis, M., Wensing, A. M. J., Bierman, W. F. W., de Jong, D., Kagan, R. M., Fun, A., Jaspers, C. A. J. J., Schurink, C. A. M., Agtmael, M. A., & Boucher, C. A. B. (2009). Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V. Journal of Infectious Diseases, 200(5), 698-709. http://www.ncbi.nlm.nih.gov/pubmed/19627247

@article{436f4fa61f8540aca5f5dbbdbe7918a2,

title = "Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V.",

author = "M. Nijhuis and A.M.J. Wensing and W.F.W Bierman and {de Jong}, D. and R.M. Kagan and A. Fun and C.A.J.J. Jaspers and C.A.M. Schurink and M.A. Agtmael and C.A.B. Boucher",

year = "2009",

language = "Undefined/Unknown",

volume = "200",

pages = "698--709",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

Nijhuis, M , Wensing, AMJ, Bierman, WFW, de Jong, D, Kagan, RM, Fun, A, Jaspers, CAJJ, Schurink, CAM, Agtmael, MA & Boucher, CAB 2009, 'Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V.', Journal of Infectious Diseases, vol. 200, no. 5, pp. 698-709. <http://www.ncbi.nlm.nih.gov/pubmed/19627247>

TY - JOUR

T1 - Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V.

AU - Nijhuis, M.

AU - Wensing, A.M.J.

AU - Bierman, W.F.W

AU - de Jong, D.

AU - Kagan, R.M.

AU - Fun, A.

AU - Jaspers, C.A.J.J.

AU - Schurink, C.A.M.

AU - Agtmael, M.A.

AU - Boucher, C.A.B.

PY - 2009

Y1 - 2009

M3 - Article

SN - 0022-1899

VL - 200

SP - 698

EP - 709

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -